The triptans. Export

@article{citeulike:4449342, abstract = {The migraine-specific triptans have revolutionized the treatment of migraine and are currently the drugs of choice to treat a migraine attack in progress. Over the past 15 years, triptans were released in rapid succession, with each one demonstrating some specific pharmacokinetic properties that may be translated into clinical advantages. Triptans share many similarities, but also have important differences from one another. Accordingly, herein we discuss the class of the triptans. We first define the trigeminovascular system and its importance in migraine pain, then discuss the mechanism of action of the triptans and contrast the evidence supporting the use of different triptans. We close with our view of the future and hopes for the next generation of antimigraine therapies.}, author = {Bigal, M. E. and Krymchantowski, A. V. and Hargreaves, R.}, citeulike-article-id = {4449342}, citeulike-linkout-0 = {http://dx.doi.org/10.1586/ern.09.15}, citeulike-linkout-1 = {http://www.ingentaconnect.com/content/ftd/ern/2009/00000009/00000005/art00009}, citeulike-linkout-2 = {http://view.ncbi.nlm.nih.gov/pubmed/19402776}, citeulike-linkout-3 = {http://www.hubmed.org/display.cgi?uids=19402776}, doi = {10.1586/ern.09.15}, issn = {1744-8360}, journal = {Expert review of neurotherapeutics}, keywords = {migraine, triptans}, month = {May}, number = {5}, pages = {649--659}, posted-at = {2009-07-09 02:33:16}, priority = {3}, publisher = {Expert Reviews}, title = {The triptans.}, url = {http://dx.doi.org/10.1586/ern.09.15}, volume = {9}, year = {2009} }

TY - JOUR ID - citeulike:4449342 L3 - citeulike-article-id:4449342 N2 - The migraine-specific triptans have revolutionized the treatment of migraine and are currently the drugs of choice to treat a migraine attack in progress. Over the past 15 years, triptans were released in rapid succession, with each one demonstrating some specific pharmacokinetic properties that may be translated into clinical advantages. Triptans share many similarities, but also have important differences from one another. Accordingly, herein we discuss the class of the triptans. We first define the trigeminovascular system and its importance in migraine pain, then discuss the mechanism of action of the triptans and contrast the evidence supporting the use of different triptans. We close with our view of the future and hopes for the next generation of antimigraine therapies. IS - 5 JF - Expert review of neurotherapeutics SN - 1744-8360 EP - 659 TI - The triptans. PB - Expert Reviews VL - 9 SP - 649 KW - migraine KW - triptans AU - Bigal, ME AU - Krymchantowski, AV AU - Hargreaves, R PY - 2009/05// UR - http://dx.doi.org/10.1586/ern.09.15 ER -